Press release
Scientifically Proven Treatment for Alzheimer's Disease and Dementia Now Available Across the USA and Canada
The forBetterMinds program utilizes cognitive stimulation therapy (CST), delivered through interactive, virtual one-on-one sessions. These sessions are conducted via Zoom by certified forBetterMinds CST Coaches and consist of 14 one-hour interactive sessions over seven weeks. This structured yet flexible approach provides comprehensive dementia care in the comfort of one's home.
Cognitive Stimulation therapy has been rigorously tested and proven to deliver significant benefits, making it a trusted method in the UK for decades. Now, it is available to people in the USA and Canada who are living with mild cognitive impairment (MCI), as well as early to mid-stage Alzheimer's Disease, Lewy Body dementia, and vascular dementia.
In light of the limited effectiveness of drug treatments for dementia, researchers have developed cognitive stimulation therapy to slow the progression of dementia and alleviate its symptoms. CST offers a non-pharmacological alternative that has shown remarkable results in enhancing the mental functions of individuals. It is an essential tool for those seeking to improve their quality of life and maintain independence for as long as possible.
People living with dementia and mild cognitive impairment in any town or city across the USA and Canada can now access the benefits of CST through forBetterMinds' telehealth delivery. The virtual format eliminates geographical barriers, ensuring that high-quality care is available to everyone, regardless of location.
The benefits of CST are manifold, including:
*
Enhanced memory
*
Improved understanding of conversations
*
Better word-finding ability
*
Increased awareness of time and place
*
Enhanced ability to follow instructions
These improvements contribute significantly to the quality of life for individuals with dementia and their caregivers, allowing them to stay in their homes longer and enjoy more fulfilling lives.
forBetterMinds is dedicated to improving the lives of people with dementia and their caregivers. By offering this scientifically proven, evidence-based therapy, the company aims to slow the progress of dementia, increase the quality of life for individuals, and provide essential support for caregivers.
About forBetterMinds
forBetterMinds, a leader in cognitive health, has been at the forefront of dementia care innovation. Their mission is to provide accessible, effective treatments that enhance the lives of those affected by dementia and cognitive impairments. With a strong foundation in the UK, forBetterMinds is proud to serve the USA and Canada, bringing world-class care to your doorstep.
To learn more about forBetterMinds and the benefits of Cognitive Stimulation Therapy, visit forbetterminds.com [https://forbetterminds.com/] and follow them on Facebook [https://www.facebook.com/forbetterminds]and Instagram [https://www.instagram.com/forbetterminds/].
Location: https://www.google.com/maps/embed?pb=!1m14!1m8!1m3!1d11538.264586211555!2d-79.3973321!3d43.6987823!3m2!1i1024!2i768!4f13.1!3m3!1m2!1s0x882b33b3c852b97d%3A0xc7686fdf2518bd19!2sforBetterMinds!5e0!3m2!1sen!2s!4v1721069297104!5m2!1sen!2s
Media Contact
Company Name: forBetterMinds
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=scientifically-proven-treatment-for-alzheimers-disease-and-dementia-now-available-across-the-usa-and-canada]
Address:1920 Yonge St Suite 200
City: Toronto
State: ON M4S 3E2
Country: Canada
Website: https://forbetterminds.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Scientifically Proven Treatment for Alzheimer's Disease and Dementia Now Available Across the USA and Canada here
News-ID: 3582184 • Views: …
More Releases from ABNewswire
Headlamp Order Delivery Adjustment Notice
On the occasion of the Spring Festival in China, Ningbo Mengting Outdoor implement Co., Ltd. [https://www.mtoutdoorlight.com/contact-us/]would like to thank all our customers for their support in 2025.
Amid the booming outdoor gear market, our outdoor headlamp factory has been steadfastly advancing all operations with the core objectives of 'stabilizing production, enhancing quality, and expanding markets,' achieving steady corporate growth.
In production management, we optimized workflows, refined task allocation, and enhanced staff training,…
Graphite Heating Element Max Temperature: What Limits It in Air vs Vacuum?
Graphite heating elements [https://www.vet-china.com/graphite-heater/page/2/], as high-temperature heating devices, are widely used in many industries, including metallurgy, electronics, semiconductors, and chemicals. Graphite materials have excellent thermal conductivity, high-temperature resistance, and chemical stability, allowing them to maintain stable operation for extended periods, especially in high-temperature environments. However, the maximum working temperature of graphite heating elements is influenced by various factors, with significant differences in temperature limits between air and vacuum environments.
Image: https://www.vet-china.com/uploads/Graphite-Heating-Element1-.png
In…
What is the Silicon Epitaxy Process? Industry Trends and Highlights
In modern integrated circuit and power device manufacturing, the silicon epitaxy [https://www.semi-cera.com/silicon-carbide-epitaxy-product/]process has become one of the fundamental key technologies. Silicon epitaxy refers to the growth of a single-crystal silicon film on the surface of a single-crystal silicon substrate, with crystal orientation and lattice continuity consistent with the substrate. The thickness, doping type and concentration, as well as defect level of this epitaxial layer can all be precisely engineered as…
Are users still looking for the perfect affordable POS solution for their busine …
Tablets POS will be the good choice for you . It has large touch screens, better visibility, and accessibility, and with the technological improvements of recent years, the powerful processors is allowing them to run complex apps.
However, a tablet point-of-sale [https://www.hosoton.com/h101-android-10-1inch-biometric-tablet-pc-for-digital-fintech-industry-product/] is not complex, nor difficult to use - in fact, you can use these incredible tools to create a technological infrastructure in your restaurant or hospitality easily.
Image: https://www.hosoton.com/uploads/Tablet-payment-pos-system-for-customer-display.jpg
In this…
More Releases for Alzheimer
Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928
Key Takeaways
• Disease-modifying…
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
